Cardio Diagnostics launched a revolutionary Blood Test for the early detection of Coronary Heart Disease

Cardiovascular diseases (CVD) continue to be the leading cause of death in the United States, with coronary heart disease (CHD) being the most common type of CVD and the primary cause of heart attacks. The American Heart Association reported nearly 400,000 deaths in 2020 are attributable to CHD, and over 800,000 Americans have a heart attack yearly. 

Cardio Diagnostics in its new patent-pending test, PrecisionCHD, will aid the early detection of coronary heart disease for the early management of the condition and better prevent a symptomatic event such as a heart attack.


Through epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers along with a proprietary machine-learning model developed by analyzing billions of genomic and epigenomic data points, PrecisionCHD is capable of detecting coronary heart disease with 75% sensitivity in both men and women.

PrecisionCHD’s key features include the ability to map a patient’s unique biomarker profile onto modifiable risk factors such as diabetes, hypertension, hypercholesterolemia, and smoking, known to be critical drivers of coronary heart disease.




“The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I’m beyond thrilled that we’re able to make the promise of precision cardiovascular medicine a reality,” said Robert Philibert, MD Ph.D., the company’s Chief Medical Officer and Co-Founder. “Clinicians seeking to assess coronary heart disease status in their patients no longer have to worry about their ability to obtain an exercise stress test or angiogram. Now, clinicians can have a blood sample drawn in their office or a kit sent to their patient’s home for this highly sensitive test.”

PrecisionCHD gives providers a complement to traditional CHD diagnostic solutions. The test is non-invasive, simple, and provides an informative, personalized patient report of CHD status.

The U.S. launch of PrecisionCHD will first be available exclusively for existing customers, with a nationwide roll-out expected shortly thereafter.

Read the full story here.


Connect yourself to thousands of experts, managers, directors, and companies in blood testing labs, cardiovascular centers, and more. Achieve your goals by having the right partners with you. Grab the chance to sell your products and make business with our members today!

Join Clinical Org

in News
Texas Heart Institute announced remarkable first heart failure treatment via cell therapy